Pembrolizumab plus lenvatinib for all advanced endometrial cancer? Maybe not

被引：1
|
作者：
Paulino, Eduardo [1 ]
机构：
[1] Brazilian Natl Canc Inst, BR-20081250 Rio De Janeiro, Brazil
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2022年 / 32卷 / 04期
关键词：
D O I：
10.1136/ijgc-2022-003419
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：579 / 579
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of pembrolizumab plus chemotherapy for advanced endometrial cancer
    Huo, Gengwei
    Song, Ying
    Chen, Peng
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (06)
  • [42] A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma
    Movva, Sujana
    Avutu, Viswatej
    Chi, Ping
    Dickson, Mark Andrew
    Gounder, Mrinal M.
    Kelly, Ciara Marie
    Keohan, Mary Louise
    Meyers, Paul A.
    Cohen, Seth M.
    Hensley, Martee Leigh
    Konner, Jason A.
    Schram, Alison M.
    Lefkowitz, Robert A.
    Erinjeri, Joseph Patrick
    Qin, Li-Xuan
    Salcito, Tiffany
    Seier, Kenneth
    Tap, William D.
    D'Angelo, Sandra P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma
    Movva, Sujana
    Avutu, Viswatej
    Chi, Ping
    Dickson, Mark Andrew
    Gounder, Mrinal M.
    Kelly, Ciara Marie
    Keohan, Mary Louise
    Nacev, Benjamin Alexander
    Rosenbaum, Evan
    Thornton, Katherine Anne
    Cohen, Seth M.
    Hensley, Martee Leigh
    Konner, Jason A.
    Schram, Alison M.
    Qin, Li-Xuan
    Lefkowitz, Robert A.
    Erinjeri, Joseph Patrick
    D'Angelo, Sandra P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma
    Hunt, Jonathan T.
    Chambers, Laura M.
    Yao, Meng
    Joehlin-Price, Amy
    Debernardo, Robert
    Rose, Peter G.
    GYNECOLOGIC ONCOLOGY REPORTS, 2021, 37
  • [45] Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
    Motzer, Robert
    Alekseev, Boris
    Rha, Sun-Young
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Gruenwald, Viktor
    Hutson, Thomas E.
    Kopyltsov, Evgeny
    Mendez-Vidal, Maria J.
    Kozlov, Vadim
    Alyasova, Anna
    Hong, Sung-Hoo
    Kapoor, Anil
    Alonso Gordoa, Teresa
    Merchan, Jaime R.
    Winquist, Eric
    Maroto, Pablo
    Goh, Jeffrey C.
    Kim, Miso
    Gurney, Howard
    Patel, Vijay
    Peer, Avivit
    Procopio, Giuseppe
    Takagi, Toshio
    Melichar, Bohuslav
    Rolland, Frederic
    De Giorgi, Ugo
    Wong, Shirley
    Bedke, Jens
    Schmidinger, Manuela
    Dutcus, Corina E.
    Smith, Alan D.
    Dutta, Lea
    Mody, Kalgi
    Perini, Rodolfo F.
    Xing, Dongyuan
    Choueiri, Toni K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (14): : 1289 - 1300
  • [46] Incidence and implications of pseudoprogression in women with advanced or recurrent endometrial cancer on pembrolizumab/lenvatinib combination therapy
    Ackroyd, Sarah
    Knickerbocker, Abbey
    Rodriguez, Gustavo
    Lippitt, Melissa
    Moore, Elena Diaz
    Vogel, Tilley Jenkins
    GYNECOLOGIC ONCOLOGY, 2023, 173 : S19 - S19
  • [47] Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice
    Lorusso, Domenica
    Colombo, Nicoletta
    Herraez, Antonio Casado
    Santin, Alessandro D.
    Colomba, Emeline
    Miller, David Scott
    Fujiwara, Keiichi
    Pignata, Sandro
    Baron-Hay, Sally E.
    Ray-Coquard, Isabelle Laure
    Shapira-Frommer, Ronnie
    Kim, Yong Man
    Mccormack, Mary
    Massaad, Rachid
    Nguyen, Allison Martin
    Zhao, Qi
    Mckenzie, Jodi
    Prabhu, Vimalanand S.
    Makker, Vicky
    EUROPEAN JOURNAL OF CANCER, 2023, 186 : 172 - 184
  • [48] Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
    Taylor, Matthew H.
    Lee, Chung-Han
    Makker, Vicky
    Rasco, Drew
    Dutcus, Corina E.
    Wu, Jane
    Stepan, Daniel E.
    Shumaker, Robert C.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (11) : 1154 - +
  • [49] CHARACTERIZATION OF ADVERSE REACTIONS IN PATIENTS WITH ADVANCED ENDOMETRIAL CANCER (AEC) RECEIVING LENVATINIB plus PEMBROLIZUMAB (STUDY 309/KEYNOTE-775)
    Colombo, N.
    Lorusso, D.
    Santin, A. D.
    Kim, Y. M.
    Herraez, A. C.
    Yonemori, K.
    Fujiwara, K.
    Colomba, E.
    Miller, D. S.
    Pignata, S.
    Monk, B. J.
    Guerra, E. M.
    Kristeleit, R.
    Orlando, M.
    Sanli, U. A.
    Dutta, L.
    Orlowski, R.
    Ren, M.
    Makker, V.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A78 - A78
  • [50] Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
    Lorusso, Domenica
    Danesi, Romano
    Locati, Laura Deborah
    Masi, Gianluca
    De Giorgi, Ugo
    Gadducci, Angiolo
    Pignata, Sandro
    Roberto, Sabbatini
    Savarese, Antonella
    Valabrega, Giorgio
    Zamagni, Claudio
    Colombo, Nicoletta
    FRONTIERS IN ONCOLOGY, 2022, 12
12345